Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT05559398

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05559398
  • EudraCT 2021-000889-16
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05559398. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-03 (actual); primary completion 2025-07-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
Acronym
GREEN
Condition
Stroke, Acute
Condition
Stroke, Ischemic
Intervention (Drug)
Glenzocimab
Intervention (Drug)
Placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct05559398
Content hash
057f5c1dc9afd00db799bdbfc01b9a90e34fd5f510730cf28fcda2bc6764f8fa